CTI cancer drug falls short in late-stage trial

Jul 09, 2018

A drug being developed by CTI Biopharma Corp. to treat a kind of blood cancer has failed in a late-stage trial.

The drug, Pixuvri, was in a phase 3 study and being tested with Roche Holding’s Rituxan to fight aggressive B-cell Non-Hodgkin lymphoma. But the drug combo did not significantly halt the progression of the disease. 

Non-Hodgkin lymphoma can affect cells in any part of the body and about 168,000 new patients are diagnosed with the disease annually in the U.S. and EU.

Upon news of the failed study, shares were down 17 percent for the company.

Read the full Reuters report.